1.A Case of Quadricuspid Aortic Valve with Aortic Regurgitation.
Noriyoshi Yamamoto ; Shigeo Imai ; Katsumi Motohiro
Japanese Journal of Cardiovascular Surgery 1994;23(4):276-279
A 61-year-old man with aortic regurgitation was found to have a quadricuspid aortic valve during operation. The aortic valve consisted of four equal sized cusps with an accessory cusp located between the left and right coronary cusps. The right coronary ostium was placed in a lower position. Aortic replacement with a St. Jude Medical prosthesis was performed successfully. Quadricuspid aortic valve is a rare anomaly and 14 cases of quadricuspid aortic valves in the Japanese literature which were corrected surgically are reviewed.
2.A Case Report of Ruptured Left Costocervical Aneurysm with Neurofibromatosis.
Noriyoshi Yamamoto ; Shigeo Imai ; Katsumi Motohiro
Japanese Journal of Cardiovascular Surgery 1994;23(5):376-379
In von Recklinghausen's disease vascular involvement is rare, especially rupture of peripheral arterial aneurysms. A 65-year-old man with previously diagnosed neurofibromatosis was admitted because of left lateral neck and left shoulder pain. Computed tomography and selective left subclavian angiography revealed ruptured aneurysm of left costocervical artery, and therefore an emergency operation was performed. Left costocervical artery was exposed and proximal ligation of the aneurysm was performed. Angiography is a most useful and important procedure in operations for vascular involvement in von Recklinghausen's disease.
3.Myocardial Protection with Differences of Administration Method of Human Superoxide Dismutase on Reperfusion Injury.
Noriyoshi YAMAMOTO ; Eiji IKEDA ; Masahiko TAKEO ; Yorikazu NAKAYAMA ; Yoshimasa SENOO ; Shigeru TERAMOTO
Japanese Journal of Cardiovascular Surgery 1993;22(1):30-35
To investigate the efficacy of human superoxide dismutase (h-SOD) in myocardial ischemia and reperfusion with difference of administration of h-SOD, twenty four dogs were subjected to 120min ischemia by the cross clamping of the ascending aorta, and followed by 60min reperfusion, The dogs were randomly assigned to three groups: group G, h-SOD (8mg/kg) was injected into the cardiopulmonary bypass (CPB) circuit 5min prior to reperfusion; group L, h-SOD (3mg/kg) was administered by bolus injection through the aortic root into the coronary artery 1min prior to reperfusion; group C, nothing was administered. The values of creatinine phosphate MB isozyme (CPK-MB) and a-hydroxydehydrogenase (HBD) in coronary effluent, and lipid peroxides (LPO) in coronary artery and sinus blood, were measured during CPB. Cardiac function was evaluated by cardiac index (C. I.) and LV max dp/dt, and it was expressed as a percent recovery of pre-CPB state. Myocardial water contents as myocardial edema were measured after CPB. Effluents of CPK-MB and HBD at 60min after reperfusion were less in group L than group G, C. Generations of LPO (A-Cs difference) were less at 5min after reperfusion in group G, L than group C and there were significant differences between group G, L and group C. The percent recovery of C. I. and LV max dp/dt at 60min after reperfusion was superior in group G, L than group C and there were significant difference between group G, L and group C. Myocardial water contents at 60min after reperfusion were less in group G, L than group C and there were significant difference between group G, L and group C. In the lipid peroxides generation, cardiac function and myocardial edema except effluents of cardiac enzymes, group G was as well as group L. These data suggest that the injection of h-SOD into the CPB circuit just before reperfusion is effective to prevent the reperfusion injury as well as the administration through the aortic root.
4.Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer
Kazuya TAKEDA ; Haruo MATSUSHITA ; Rei UMEZAWA ; Takaya YAMAMOTO ; Yojiro ISHIKAWA ; Noriyoshi TAKAHASHI ; Yu SUZUKI ; Keiichi JINGU
Radiation Oncology Journal 2021;39(4):265-269
Purpose:
Re-irradiation is a treatment option for recurrent esophageal cancer patients with a history of radiotherapy, but there is a risk of severe late adverse effects. This study focused on the efficacy and safety of re-irradiation using hyperfractionated radiotherapy.
Materials and Methods:
Twenty-six patients who underwent re-irradiation by the hyperfraction technique using twice-daily irradiation of 1.2 Gy per fraction for recurrent esophageal cancer were retrospectively included in this study. The overall survival period after the start of secondary radiotherapy and the occurrence of late adverse effects were investigated.
Results:
Of 26 patients, 21 (81%) received re-irradiation with definitive intention and 21 (81%) underwent concurrent chemotherapy. The median re-irradiation dose was 60 Gy in 50 fractions in 25 treatment days, and the median accumulated irradiation dose in equivalent dose in 2 Gy per fraction was 85.4 Gy with an α/β value of 3. The median interval between two courses of radiotherapy was 21.0 months. The median overall survival period was 15.8 months and the 1-year and 3-year overall survival rates were 64.3% and 28.3%, respectively. Higher dose of re-irradiation and concurrent chemotherapy significantly improved survival (p < 0.001 and p = 0.019, respectively). Severe late adverse effects with the Common Terminology Criteria for Adverse Events grade 3 or higher were observed in 5 (19.2%) patients, and 2 (7.7%) of them developed a grade 5 late adverse effect.
Conclusion
High-dose re-irradiation using a hyperfractionated schedule with concurrent chemotherapy might be related to good prognosis, while the rate of late severe adverse effects is not high compared with the rates in past reports.